$Ensysce Biosciences (ENSC.US)$ August 27, 2024 / Ensysce Bi...
$Ensysce Biosciences (ENSC.US)$ August 27, 2024 / Ensysce Biosciences, Inc.
(“Ensysce” or “Company”) (NASDAQ stock code: ENSC) is a clinical stage pharmaceutical company dedicated to developing innovative solutions for the relief of severe pain while reducing the potential for opioid abuse and overdose. Today, it announced that it has received approval from the Investigational Review Board (IRB) for the PF614-MPAR-102 study, a “single and multiple dose study to evaluate the pharmacokinetics of hydrocodone and PF614 when PF614 capsules are co-administered with naltrexone as an immediate-release solution and an extended-release capsule formulation in healthy subjects.” Ensysce continues to collaborate with Quotient Sciences to conduct the second MPAR clinical study using their Translational Pharmaceutics® platform.
(“Ensysce” or “Company”) (NASDAQ stock code: ENSC) is a clinical stage pharmaceutical company dedicated to developing innovative solutions for the relief of severe pain while reducing the potential for opioid abuse and overdose. Today, it announced that it has received approval from the Investigational Review Board (IRB) for the PF614-MPAR-102 study, a “single and multiple dose study to evaluate the pharmacokinetics of hydrocodone and PF614 when PF614 capsules are co-administered with naltrexone as an immediate-release solution and an extended-release capsule formulation in healthy subjects.” Ensysce continues to collaborate with Quotient Sciences to conduct the second MPAR clinical study using their Translational Pharmaceutics® platform.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
